Skip to main content
Top
Published in: BMC Nephrology 1/2018

Open Access 01-12-2018 | Research article

Relation of multi-marker panel to incident chronic kidney disease and rapid kidney function decline in African Americans: the Jackson Heart Study

Authors: Stanford E. Mwasongwe, Bessie Young, Aurelian Bidulescu, Mario Sims, Adolfo Correa, Solomon K. Musani

Published in: BMC Nephrology | Issue 1/2018

Login to get access

Abstract

Background

Few investigations have evaluated the incremental usefulness of multiple biomarkers representing varying physiological pathways for predicting risk of renal outcomes in African Americans.

Design, setting, participants, and measurements

We related a multi-marker panel to incident chronic kidney disease (CKD) and rapid kidney function decline (RKFD) in 2813 Jackson Heart Study participants without prevalent CKD at exam 1 (2000–2004) and with complete assays at exam 1 for 9 biomarkers: adiponectin, aldosterone, B-natriuretic peptide [BNP], cortisol, high sensitivity C-reactive protein (hsCRP), endothelin, homocysteine, plasma renin activity and mass. Incident CKD was defined as estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m2 at exam 3 while RKFD was defined as eGFR ≥30% loss between exams 1 and 3 (8.2 median years). We employed multiple logistic regression model to describe association between the panel and incident CKD and RKFD and used backward elimination strategy to estimate the most parsimonious biomarker model while controlling for conventional risk factors.

Results

The multi-marker panel predicted the risk for both incident CKD (odds ratios [OR], 2.72; 95% confidence intervals [CI], 1.63, 4.56; P = 0.001) and RKFD (2.61; 95% CI, 1.67, 4.08; P < 0.001). Per standard deviation increase in log biomarker concentrations were significantly (multivariable adjusted odds ratios, [95% confidence interval], p-value) associated with incident CKD: plasma adiponectin (1.24 [1.07, 1.44], p = 0.005) and leptin (1.3 [1.06, 1.61], p = 0.011), and with RKFD: plasma adiponectin (1.22 [1.06, 1.40], p = 0.006); hsCRP (1.17 [1.01, 1.36], p = 0.031) and aldosterone (0.85 [0.74, 0.96], p = 0.012). Moderate levels (3rd quartile) of aldosterone were inversely associated with incident CKD (0.54 [0.35, 0.82], p = 0.004) while leptin was associated with RKFD (1.64 [1.10, 2.44], p = 0.015). Biomarkers improved CKD risk prediction (P = 0.003) but not RKFD risk prediction (P = 0.10).

Conclusion

In this community-based sample of African Americans, a multi-marker panel added only moderate predictive improvement compared to conventional risk factors.
Appendix
Available only for authorised users
Literature
1.
go back to reference Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298(17):2038–47.CrossRef Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298(17):2038–47.CrossRef
2.
go back to reference Young BA, Katz R, Boulware LE, Kestenbaum B, de Boer IH, Wang W, Fulop T, Bansal N, Robinson-Cohen C, Griswold M, et al. Risk factors for rapid kidney function decline among African Americans: the Jackson Heart Study (JHS). Am J Kidney Dis. 2016;68(2):229–39.CrossRef Young BA, Katz R, Boulware LE, Kestenbaum B, de Boer IH, Wang W, Fulop T, Bansal N, Robinson-Cohen C, Griswold M, et al. Risk factors for rapid kidney function decline among African Americans: the Jackson Heart Study (JHS). Am J Kidney Dis. 2016;68(2):229–39.CrossRef
3.
go back to reference Zoccali C. Biomarkers in chronic kidney disease: utility and issues towards better understanding. Curr Opin Nephrol Hypertens. 2005;14(6):532–7.CrossRef Zoccali C. Biomarkers in chronic kidney disease: utility and issues towards better understanding. Curr Opin Nephrol Hypertens. 2005;14(6):532–7.CrossRef
4.
go back to reference Peralta CA, Katz R, Sarnak MJ, Ix J, Fried LF, De Boer I, Palmas W, Siscovick D, Levey AS, Shlipak MG. Cystatin C identifies chronic kidney disease patients at higher risk for complications. J Am Soc Nephrol. 2011;22(1):147–55.CrossRef Peralta CA, Katz R, Sarnak MJ, Ix J, Fried LF, De Boer I, Palmas W, Siscovick D, Levey AS, Shlipak MG. Cystatin C identifies chronic kidney disease patients at higher risk for complications. J Am Soc Nephrol. 2011;22(1):147–55.CrossRef
5.
go back to reference Weekley CC, Peralta CA. Advances in the use of multimarker panels for renal risk stratification. Curr Opin Nephrol Hypertens. 2012;21(3):301–8.CrossRef Weekley CC, Peralta CA. Advances in the use of multimarker panels for renal risk stratification. Curr Opin Nephrol Hypertens. 2012;21(3):301–8.CrossRef
6.
go back to reference Tarver-Carr ME, Powe NR, Eberhardt MS, LaVeist TA, Kington RS, Coresh J, Brancati FL. Excess risk of chronic kidney disease among African-American versus white subjects in the United States: a population-based study of potential explanatory factors. J Am Soc Nephrol. 2002;13(9):2363–70.CrossRef Tarver-Carr ME, Powe NR, Eberhardt MS, LaVeist TA, Kington RS, Coresh J, Brancati FL. Excess risk of chronic kidney disease among African-American versus white subjects in the United States: a population-based study of potential explanatory factors. J Am Soc Nephrol. 2002;13(9):2363–70.CrossRef
7.
go back to reference Dunkler D, Gao P, Lee SF, Heinze G, Clase CM, Tobe S, Teo KK, Gerstein H, Mann JF, Oberbauer R. Risk prediction for early CKD in type 2 diabetes. Clin J Am Soc Nephrol. 2015;10(8):1371–9.CrossRef Dunkler D, Gao P, Lee SF, Heinze G, Clase CM, Tobe S, Teo KK, Gerstein H, Mann JF, Oberbauer R. Risk prediction for early CKD in type 2 diabetes. Clin J Am Soc Nephrol. 2015;10(8):1371–9.CrossRef
8.
go back to reference Peters KE, Davis WA, Ito J, Winfield K, Stoll T, Bringans SD, Lipscombe RJ, Davis TME. Identification of novel circulating biomarkers predicting rapid decline in renal function in type 2 diabetes: the Fremantle diabetes study phase II. Diabetes Care. 2017;40(11):1548–55.CrossRef Peters KE, Davis WA, Ito J, Winfield K, Stoll T, Bringans SD, Lipscombe RJ, Davis TME. Identification of novel circulating biomarkers predicting rapid decline in renal function in type 2 diabetes: the Fremantle diabetes study phase II. Diabetes Care. 2017;40(11):1548–55.CrossRef
9.
go back to reference Looker HC, Colombo M, Hess S, Brosnan MJ, Farran B, Dalton RN, Wong MC, Turner C, Palmer CN, Nogoceke E, et al. Biomarkers of rapid chronic kidney disease progression in type 2 diabetes. Kidney Int. 2015;88(4):888–96.CrossRef Looker HC, Colombo M, Hess S, Brosnan MJ, Farran B, Dalton RN, Wong MC, Turner C, Palmer CN, Nogoceke E, et al. Biomarkers of rapid chronic kidney disease progression in type 2 diabetes. Kidney Int. 2015;88(4):888–96.CrossRef
10.
go back to reference Fox CS, Gona P, Larson MG, Selhub J, Tofler G, Hwang SJ, Meigs JB, Levy D, Wang TJ, Jacques PF, et al. A multi-marker approach to predict incident CKD and microalbuminuria. J Am Soc Nephrol. 2010;21(12):2143–9.CrossRef Fox CS, Gona P, Larson MG, Selhub J, Tofler G, Hwang SJ, Meigs JB, Levy D, Wang TJ, Jacques PF, et al. A multi-marker approach to predict incident CKD and microalbuminuria. J Am Soc Nephrol. 2010;21(12):2143–9.CrossRef
11.
go back to reference Gaggin HK, Januzzi JL Jr. Biomarkers and diagnostics in heart failure. Biochim Biophys Acta. 2013;1832(12):2442–50.CrossRef Gaggin HK, Januzzi JL Jr. Biomarkers and diagnostics in heart failure. Biochim Biophys Acta. 2013;1832(12):2442–50.CrossRef
12.
go back to reference Musani SK, Vasan RS, Bidulescu A, Liu J, Xanthakis V, Sims M, Gawalapu RK, Samdarshi TE, Steffes M, Taylor HA, et al. Aldosterone, C-reactive protein, and plasma B-type natriuretic peptide are associated with the development of metabolic syndrome and longitudinal changes in metabolic syndrome components: findings from the Jackson Heart Study. Diabetes Care. 2013;36(10):3084–92.CrossRef Musani SK, Vasan RS, Bidulescu A, Liu J, Xanthakis V, Sims M, Gawalapu RK, Samdarshi TE, Steffes M, Taylor HA, et al. Aldosterone, C-reactive protein, and plasma B-type natriuretic peptide are associated with the development of metabolic syndrome and longitudinal changes in metabolic syndrome components: findings from the Jackson Heart Study. Diabetes Care. 2013;36(10):3084–92.CrossRef
13.
go back to reference Ingelsson E, Pencina MJ, Tofler GH, Benjamin EJ, Lanier KJ, Jacques PF, Fox CS, Meigs JB, Levy D, Larson MG, et al. Multimarker approach to evaluate the incidence of the metabolic syndrome and longitudinal changes in metabolic risk factors: the Framingham offspring study. Circulation. 2007;116(9):984–92.CrossRef Ingelsson E, Pencina MJ, Tofler GH, Benjamin EJ, Lanier KJ, Jacques PF, Fox CS, Meigs JB, Levy D, Larson MG, et al. Multimarker approach to evaluate the incidence of the metabolic syndrome and longitudinal changes in metabolic risk factors: the Framingham offspring study. Circulation. 2007;116(9):984–92.CrossRef
14.
go back to reference Mischak H, Delles C, Vlahou A, Vanholder R. Proteomic biomarkers in kidney disease: issues in development and implementation. Nat Rev Nephrol. 2015;11(4):221–32.CrossRef Mischak H, Delles C, Vlahou A, Vanholder R. Proteomic biomarkers in kidney disease: issues in development and implementation. Nat Rev Nephrol. 2015;11(4):221–32.CrossRef
15.
go back to reference Leening MJ, Vedder MM, Witteman JC, Pencina MJ, Steyerberg EW. Net reclassification improvement: computation, interpretation, and controversies: a literature review and clinician's guide. Ann Intern Med. 2014;160(2):122-131.CrossRef Leening MJ, Vedder MM, Witteman JC, Pencina MJ, Steyerberg EW. Net reclassification improvement: computation, interpretation, and controversies: a literature review and clinician's guide. Ann Intern Med. 2014;160(2):122-131.CrossRef
16.
go back to reference Pencina MJ, D'Agostino RB Sr, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med. 2011;30(1):11–21.CrossRef Pencina MJ, D'Agostino RB Sr, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med. 2011;30(1):11–21.CrossRef
17.
go back to reference Fuqua SR, Wyatt SB, Andrew ME, Sarpong DF, Henderson FR, Cunningham MF, Taylor HA Jr. Recruiting African-American research participation in the Jackson Heart Study: methods, response rates, and sample description. Ethn Dis. 2005;15(4 Suppl 6):S6–18-29.PubMed Fuqua SR, Wyatt SB, Andrew ME, Sarpong DF, Henderson FR, Cunningham MF, Taylor HA Jr. Recruiting African-American research participation in the Jackson Heart Study: methods, response rates, and sample description. Ethn Dis. 2005;15(4 Suppl 6):S6–18-29.PubMed
18.
go back to reference Sempos CT, Bild DE, Manolio TA. Overview of the Jackson Heart Study: a study of cardiovascular diseases in african american men and women. Am J Med Sci. 1999;317(3):142-46.CrossRef Sempos CT, Bild DE, Manolio TA. Overview of the Jackson Heart Study: a study of cardiovascular diseases in african american men and women. Am J Med Sci. 1999;317(3):142-46.CrossRef
19.
go back to reference Carpenter MA, Crow R, Steffes M, Rock W, Heilbraun J, Evans G, Skelton T, Jensen R, Sarpong D. Laboratory, reading center, and coordinating center data management methods in the Jackson Heart Study. Am J Med Sci. 2004;328(3):131–44.CrossRef Carpenter MA, Crow R, Steffes M, Rock W, Heilbraun J, Evans G, Skelton T, Jensen R, Sarpong D. Laboratory, reading center, and coordinating center data management methods in the Jackson Heart Study. Am J Med Sci. 2004;328(3):131–44.CrossRef
20.
go back to reference Rebholz CM, Harman JL, Grams ME, Correa A, Shimbo D, Coresh J, Young BA. Association between endothelin-1 levels and kidney disease among blacks. J Am Soc Nephrol. 2017;28(11):3337-44.CrossRef Rebholz CM, Harman JL, Grams ME, Correa A, Shimbo D, Coresh J, Young BA. Association between endothelin-1 levels and kidney disease among blacks. J Am Soc Nephrol. 2017;28(11):3337-44.CrossRef
21.
go back to reference Wang W, Young BA, Fulop T, de Boer IH, Boulware LE, Katz R, Correa A, Griswold ME. Effects of serum creatinine calibration on estimated renal function in african americans: the Jackson Heart Study. Am J Med Sci. 2015;349(5):379–84.CrossRef Wang W, Young BA, Fulop T, de Boer IH, Boulware LE, Katz R, Correa A, Griswold ME. Effects of serum creatinine calibration on estimated renal function in african americans: the Jackson Heart Study. Am J Med Sci. 2015;349(5):379–84.CrossRef
22.
go back to reference Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, Kusek JW, Manzi J, Van Lente F, Zhang YL, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med. 2012;367(1):20–9.CrossRef Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, Kusek JW, Manzi J, Van Lente F, Zhang YL, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med. 2012;367(1):20–9.CrossRef
23.
go back to reference Shlipak MG, Katz R, Kestenbaum B, Siscovick D, Fried L, Newman A, Rifkin D, Sarnak MJ. Rapid decline of kidney function increases cardiovascular risk in the elderly. J Am Soc Nephrol. 2009;20(12):2625–30.CrossRef Shlipak MG, Katz R, Kestenbaum B, Siscovick D, Fried L, Newman A, Rifkin D, Sarnak MJ. Rapid decline of kidney function increases cardiovascular risk in the elderly. J Am Soc Nephrol. 2009;20(12):2625–30.CrossRef
24.
go back to reference Bash LD, Coresh J, Kottgen A, Parekh RS, Fulop T, Wang Y, Astor BC. Defining incident chronic kidney disease in the research setting: the ARIC study. Am J Epidemiol. 2009;170(4):414–24.CrossRef Bash LD, Coresh J, Kottgen A, Parekh RS, Fulop T, Wang Y, Astor BC. Defining incident chronic kidney disease in the research setting: the ARIC study. Am J Epidemiol. 2009;170(4):414–24.CrossRef
25.
go back to reference Coresh J, Turin TC, Matsushita K, Sang Y, Ballew SH, Appel LJ, Arima H, Chadban SJ, Cirillo M, Djurdjev O, et al. Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. Jama. 2014;311(24):2518–31.CrossRef Coresh J, Turin TC, Matsushita K, Sang Y, Ballew SH, Appel LJ, Arima H, Chadban SJ, Cirillo M, Djurdjev O, et al. Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. Jama. 2014;311(24):2518–31.CrossRef
26.
go back to reference Stevens LA, Schmid CH, Greene T, Zhang YL, Beck GJ, Froissart M, Hamm LL, Lewis JB, Mauer M, Navis GJ, et al. Comparative performance of the CKD epidemiology collaboration (CKD-EPI) and the modification of diet in renal disease (MDRD) study equations for estimating GFR levels above 60 mL/min/1.73 m2. Am J Kidney Dis. 2010;56(3):486–95.CrossRef Stevens LA, Schmid CH, Greene T, Zhang YL, Beck GJ, Froissart M, Hamm LL, Lewis JB, Mauer M, Navis GJ, et al. Comparative performance of the CKD epidemiology collaboration (CKD-EPI) and the modification of diet in renal disease (MDRD) study equations for estimating GFR levels above 60 mL/min/1.73 m2. Am J Kidney Dis. 2010;56(3):486–95.CrossRef
27.
go back to reference Hiramoto JS, Katz R, Peralta CA, Ix JH, Fried L, Cushman M, Siscovick D, Palmas W, Sarnak M, Shlipak MG. Inflammation and coagulation markers and kidney function decline: the multi-ethnic study of atherosclerosis (MESA). Am J Kidney Dis. 2012;60(2):225–32.CrossRef Hiramoto JS, Katz R, Peralta CA, Ix JH, Fried L, Cushman M, Siscovick D, Palmas W, Sarnak M, Shlipak MG. Inflammation and coagulation markers and kidney function decline: the multi-ethnic study of atherosclerosis (MESA). Am J Kidney Dis. 2012;60(2):225–32.CrossRef
28.
go back to reference Taylor HA Jr, Wilson JG, Jones DW, Sarpong DF, Srinivasan A, Garrison RJ, Nelson C, Wyatt SB. Toward resolution of cardiovascular health disparities in African Americans: design and methods of the Jackson Heart Study. Ethn Dis. 2005;15(4 Suppl 6):S6–4. 17PubMed Taylor HA Jr, Wilson JG, Jones DW, Sarpong DF, Srinivasan A, Garrison RJ, Nelson C, Wyatt SB. Toward resolution of cardiovascular health disparities in African Americans: design and methods of the Jackson Heart Study. Ethn Dis. 2005;15(4 Suppl 6):S6–4. 17PubMed
29.
go back to reference Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Omland T, Wolf PA, Vasan RS. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med. 2004;350(7):655–63.CrossRef Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Omland T, Wolf PA, Vasan RS. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med. 2004;350(7):655–63.CrossRef
30.
go back to reference Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008;27(2):157–72. discussion 207-112CrossRef Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008;27(2):157–72. discussion 207-112CrossRef
31.
go back to reference Liu Y, De A. Multiple imputation by fully conditional specification for dealing with missing data in a large epidemiologic study. Int J Stat Med Res. 2015;4(3):287–95.CrossRef Liu Y, De A. Multiple imputation by fully conditional specification for dealing with missing data in a large epidemiologic study. Int J Stat Med Res. 2015;4(3):287–95.CrossRef
32.
go back to reference Kennedy K, Pencina M: A SAS® macro to compute added predictive ability of new markers predicting a dichotomous outcome. SouthEeast SAS users group annual meeting proceedings 2010. Kennedy K, Pencina M: A SAS® macro to compute added predictive ability of new markers predicting a dichotomous outcome. SouthEeast SAS users group annual meeting proceedings 2010.
33.
go back to reference Lim CC, Teo BW, Tai ES, Lim SC, Chan CM, Sethi S, Wong TY, Sabanayagam C. Elevated serum leptin, adiponectin and leptin to adiponectin ratio is associated with chronic kidney disease in Asian adults. PLoS One. 2015;10(3):e0122009.CrossRef Lim CC, Teo BW, Tai ES, Lim SC, Chan CM, Sethi S, Wong TY, Sabanayagam C. Elevated serum leptin, adiponectin and leptin to adiponectin ratio is associated with chronic kidney disease in Asian adults. PLoS One. 2015;10(3):e0122009.CrossRef
34.
go back to reference Mills KT, Hamm LL, Alper AB, Miller C, Hudaihed A, Balamuthusamy S, Chen CS, Liu Y, Tarsia J, Rifai N, et al. Circulating adipocytokines and chronic kidney disease. PLoS One. 2013;8(10):e76902.CrossRef Mills KT, Hamm LL, Alper AB, Miller C, Hudaihed A, Balamuthusamy S, Chen CS, Liu Y, Tarsia J, Rifai N, et al. Circulating adipocytokines and chronic kidney disease. PLoS One. 2013;8(10):e76902.CrossRef
35.
go back to reference Guebre-Egziabher F, Bernhard J, Funahashi T, Hadj-Aissa A, Fouque D. Adiponectin in chronic kidney disease is related more to metabolic disturbances than to decline in renal function. Nephrol Dial Transplant. 2005;20(1):129–34.CrossRef Guebre-Egziabher F, Bernhard J, Funahashi T, Hadj-Aissa A, Fouque D. Adiponectin in chronic kidney disease is related more to metabolic disturbances than to decline in renal function. Nephrol Dial Transplant. 2005;20(1):129–34.CrossRef
36.
go back to reference Yaturu S, Reddy RD, Rains J, Jain SK. Plasma and urine levels of resistin and adiponectin in chronic kidney disease. Cytokine. 2007;37(1):1–5.CrossRef Yaturu S, Reddy RD, Rains J, Jain SK. Plasma and urine levels of resistin and adiponectin in chronic kidney disease. Cytokine. 2007;37(1):1–5.CrossRef
37.
go back to reference Becker B, Kronenberg F, Kielstein JT, Haller H, Morath C, Ritz E, Fliser D. Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the mild and moderate kidney disease study. J Am Soc Nephrol. 2005;16(4):1091–8.CrossRef Becker B, Kronenberg F, Kielstein JT, Haller H, Morath C, Ritz E, Fliser D. Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the mild and moderate kidney disease study. J Am Soc Nephrol. 2005;16(4):1091–8.CrossRef
38.
go back to reference Briffa JF, McAinch AJ, Poronnik P, Hryciw DH. Adipokines as a link between obesity and chronic kidney disease. Am J Physiol Renal Physiol. 2013;305(12):F1629–36.CrossRef Briffa JF, McAinch AJ, Poronnik P, Hryciw DH. Adipokines as a link between obesity and chronic kidney disease. Am J Physiol Renal Physiol. 2013;305(12):F1629–36.CrossRef
39.
go back to reference Ruster C, Wolf G. Adipokines promote chronic kidney disease. Nephrol Dial Transplant. 2013;28(Suppl 4):iv8–14.CrossRef Ruster C, Wolf G. Adipokines promote chronic kidney disease. Nephrol Dial Transplant. 2013;28(Suppl 4):iv8–14.CrossRef
40.
go back to reference Terata S, Kikuya M, Satoh M, Ohkubo T, Hashimoto T, Hara A, Hirose T, Obara T, Metoki H, Inoue R, et al. Plasma renin activity and the aldosterone-to-renin ratio are associated with the development of chronic kidney disease: the Ohasama study. J Hypertens. 2012;30(8):1632–8.CrossRef Terata S, Kikuya M, Satoh M, Ohkubo T, Hashimoto T, Hara A, Hirose T, Obara T, Metoki H, Inoue R, et al. Plasma renin activity and the aldosterone-to-renin ratio are associated with the development of chronic kidney disease: the Ohasama study. J Hypertens. 2012;30(8):1632–8.CrossRef
41.
go back to reference Jurgens G, Graudal NA. Effects of low sodium diet versus high sodium diet on blood pressure, renin, aldosterone, catecholamines, cholesterols, and triglyceride. Cochrane Database Syst Rev. 2004;(1):Cd004022. Jurgens G, Graudal NA. Effects of low sodium diet versus high sodium diet on blood pressure, renin, aldosterone, catecholamines, cholesterols, and triglyceride. Cochrane Database Syst Rev. 2004;(1):Cd004022.
42.
go back to reference Fox ER, Benjamin EJ, Sarpong DF, Nagarajarao H, Taylor JK, Steffes MW, Salahudeen AK, Flessner MF, Akylbekova EL, Fox CS, et al. The relation of C--reactive protein to chronic kidney disease in African Americans: the Jackson Heart Study. BMC Nephrol. 2010;11(1). Fox ER, Benjamin EJ, Sarpong DF, Nagarajarao H, Taylor JK, Steffes MW, Salahudeen AK, Flessner MF, Akylbekova EL, Fox CS, et al. The relation of C--reactive protein to chronic kidney disease in African Americans: the Jackson Heart Study. BMC Nephrol. 2010;11(1).
43.
go back to reference Shankar A, Sun L, Klein BE, Lee KE, Muntner P, Nieto FJ, Tsai MY, Cruickshanks KJ, Schubert CR, Brazy PC, et al. Markers of inflammation predict the long-term risk of developing chronic kidney disease: a population-based cohort study. Kidney Int. 2011;80(11):1231–8.CrossRef Shankar A, Sun L, Klein BE, Lee KE, Muntner P, Nieto FJ, Tsai MY, Cruickshanks KJ, Schubert CR, Brazy PC, et al. Markers of inflammation predict the long-term risk of developing chronic kidney disease: a population-based cohort study. Kidney Int. 2011;80(11):1231–8.CrossRef
44.
go back to reference Remuzzi G, Cattaneo D, Perico N. The aggravating mechanisms of aldosterone on kidney fibrosis. J Am Soc Nephrol. 2008;19(8):1459–62.CrossRef Remuzzi G, Cattaneo D, Perico N. The aggravating mechanisms of aldosterone on kidney fibrosis. J Am Soc Nephrol. 2008;19(8):1459–62.CrossRef
45.
go back to reference Del Vecchio L, Procaccio M, Vigano S, Cusi D. Mechanisms of disease: the role of aldosterone in kidney damage and clinical benefits of its blockade. Nat Clin Pract Nephrol. 2007;3(1):42–9.CrossRef Del Vecchio L, Procaccio M, Vigano S, Cusi D. Mechanisms of disease: the role of aldosterone in kidney damage and clinical benefits of its blockade. Nat Clin Pract Nephrol. 2007;3(1):42–9.CrossRef
46.
go back to reference Hannemann A, Rettig R, Dittmann K, Volzke H, Endlich K, Nauck M, Wallaschofski H. Aldosterone and glomerular filtration--observations in the general population. BMC Nephrol. 2014;15:44.CrossRef Hannemann A, Rettig R, Dittmann K, Volzke H, Endlich K, Nauck M, Wallaschofski H. Aldosterone and glomerular filtration--observations in the general population. BMC Nephrol. 2014;15:44.CrossRef
47.
go back to reference Stepien M, Stepien A, Wlazel RN, Paradowski M, Banach M, Rysz M, Rysz J. Obesity indices and adipokines in non-diabetic obese patients with early stages of chronic kidney disease. Med Sci Monit. 2013;19:1063–72.CrossRef Stepien M, Stepien A, Wlazel RN, Paradowski M, Banach M, Rysz M, Rysz J. Obesity indices and adipokines in non-diabetic obese patients with early stages of chronic kidney disease. Med Sci Monit. 2013;19:1063–72.CrossRef
48.
go back to reference May A, Wang TJ. Biomarkers for cardiovascular disease: challenges and future directions. Trends Mol Med. 2008;14(6):261–7.CrossRef May A, Wang TJ. Biomarkers for cardiovascular disease: challenges and future directions. Trends Mol Med. 2008;14(6):261–7.CrossRef
49.
go back to reference Cook NR. Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation. 2007;115(7):928–35.CrossRef Cook NR. Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation. 2007;115(7):928–35.CrossRef
50.
go back to reference Wang TJ, Gona P, Larson MG, Tofler GH, Levy D, Newton-Cheh C, Jacques PF, Rifai N, Selhub J, Robins SJ, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med. 2006;355(25):2631–9.CrossRef Wang TJ, Gona P, Larson MG, Tofler GH, Levy D, Newton-Cheh C, Jacques PF, Rifai N, Selhub J, Robins SJ, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med. 2006;355(25):2631–9.CrossRef
51.
go back to reference Melander O, Newton-Cheh C, Almgren P, Hedblad B, Berglund G, Engstrom G, Persson M, Smith JG, Magnusson M, Christensson A, et al. Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. JAMA. 2009;302(1):49–57.CrossRef Melander O, Newton-Cheh C, Almgren P, Hedblad B, Berglund G, Engstrom G, Persson M, Smith JG, Magnusson M, Christensson A, et al. Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. JAMA. 2009;302(1):49–57.CrossRef
52.
go back to reference Kavousi M, Desai CS, Ayers C, Blumenthal RS, Budoff MJ, Mahabadi AA, Ikram MA, van der Lugt A, Hofman A, Erbel R, et al. Prevalence and prognostic implications of coronary artery calcification in low-risk women: a meta-analysis. JAMA. 2016;316(20):2126–34.CrossRef Kavousi M, Desai CS, Ayers C, Blumenthal RS, Budoff MJ, Mahabadi AA, Ikram MA, van der Lugt A, Hofman A, Erbel R, et al. Prevalence and prognostic implications of coronary artery calcification in low-risk women: a meta-analysis. JAMA. 2016;316(20):2126–34.CrossRef
53.
go back to reference Zethelius B, Berglund L, Sundstrom J, Ingelsson E, Basu S, Larsson A, Venge P, Arnlov J. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med. 2008;358(20):2107–16.CrossRef Zethelius B, Berglund L, Sundstrom J, Ingelsson E, Basu S, Larsson A, Venge P, Arnlov J. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med. 2008;358(20):2107–16.CrossRef
54.
go back to reference Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds risk score. Jama. 2007;297(6):611–9.CrossRef Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds risk score. Jama. 2007;297(6):611–9.CrossRef
55.
go back to reference Velagaleti RS, Gona P, Larson MG, Wang TJ, Levy D, Benjamin EJ, Selhub J, Jacques PF, Meigs JB, Tofler GH, et al. Multimarker approach for the prediction of heart failure incidence in the community. Circulation. 2010;122(17):1700–6.CrossRef Velagaleti RS, Gona P, Larson MG, Wang TJ, Levy D, Benjamin EJ, Selhub J, Jacques PF, Meigs JB, Tofler GH, et al. Multimarker approach for the prediction of heart failure incidence in the community. Circulation. 2010;122(17):1700–6.CrossRef
Metadata
Title
Relation of multi-marker panel to incident chronic kidney disease and rapid kidney function decline in African Americans: the Jackson Heart Study
Authors
Stanford E. Mwasongwe
Bessie Young
Aurelian Bidulescu
Mario Sims
Adolfo Correa
Solomon K. Musani
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2018
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-018-1026-y

Other articles of this Issue 1/2018

BMC Nephrology 1/2018 Go to the issue